logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Cost comparison of bêta2-agonist bronchodilators used in the treatment of asthma.

    Article - En anglais

    Because of increases in the morbidity and mortality associated with asthma, coupled with shrinking health care resources, the costs associated with therapy with bêta2-agonists in metered-dose inhalers (MDIs), the most frequently used class of therapeutic agents, were examined.

    Recent recommendations suggested a change in drug therapy for asthma, away from theophylline and toward patient-administered MDIs containing bêta2-agonists or corticosteroids.

    These recommendations are expected ultimately to reduce overall costs by decreasing morbidity due to asthma and by reducing hospital services.

    Furthermore, differences exist among the various bêta2-agonists.

    For example, for patients treated with albuterol inhalers, total asthma drug costs, the costs of additional asthma drugs, and hospital costs were lower than those for patients treated with metaproterenol inhalers, despite the higher acquisition cost of albuterol.

    Using the maximum recommended number of daily inhalations and standardized pricing data, the daily costs of nine individual bêta2-agonists in MDIs were calculated.

    These varied from $0.61 for albuterol to $1.28 for pirbuterol, but would be lower for patients who required fewer daily inhalations on an as-needed basis.

    In addition, agents that can be dosed as needed (i.e., albuterol) are likely to be more cost-effective choices for formularies than more expensive new bronchodilators such as salmeterol, which must be given twice/day on a regular basis.

    Mots-clés Pascal : Bronchodilatateur, Antiasthmatique, Agoniste, Récepteur bêta2-adrénergique, Chimiothérapie, Asthme, Homme, Etude comparative, Coût, Economie santé, Traitement, Aérosol doseur, Etats Unis, Amérique du Nord, Amérique, Appareil respiratoire pathologie, Bronchopneumopathie obstructive

    Mots-clés Pascal anglais : Bronchodilator, Antiasthma agent, Agonist, bêta2-Adrenergic receptor, Chemotherapy, Asthma, Human, Comparative study, Costs, Health economy, Treatment, Aerosol batcher, United States, North America, America, Respiratory disease, Obstructive pulmonary disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 95-0552218

    Code Inist : 002B02D. Création : 01/03/1996.